VanEck非必需消費品TruSector主動型ETF TRUD 深 滬
已收盤 02-06 16:00:00 美东时间
25.3714
-0.157
-0.62%
華盛通- 最 高25.3714
- 今 開24.78
- 成交量 22.73万股
- 最 低 24.6975
- 昨 收 25.5288
- 總市值 2334.17万
- 52周最高 27.50
- 市盈率 靜 --
- 換手率 24.71%
- 52周最低 24.214
- 委 比 0.00%
- 總股本 92.00万
- 歷史最高 27.50
- 量 比 1.85
- 振 幅 2.64%
- 歷史最低 24.214
- 每 手 1
- 風險率 0.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Achieves 50% Participant Enrollment Target In TACTI-004 Phase III Study Evaluating Eftilagimod Alfa In Combination With Merck's Anti-PD-1 Therapy
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient enrolment target in
02-06 21:04
Merck Q4 revenue misses estimates on lower Gardasil demand
Merck Q4 revenue misses estimates on lower Gardasil demand Overview Pharmaceutical firm's Q4 revenue grew 5% but missed analyst expectations Adjusted EPS for Q4 beat analyst expectations Company highlighted progress in pipeline and acquisitions Outlook Merck anticipates 2026 sales between $65.5 bln
02-03 19:39
Merck posts Q4 diluted EPS of USD 1.19, down 20%
Merck posts Q4 diluted EPS of USD 1.19, down 20% Merck & Co. Inc. reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, net income attributable to shareholders was USD 2.96 billion, with diluted earnings per share (EPS) of USD 1.19. For the full year 2025,
02-03 19:31
BRIEF-Merck Expects 2026 Sales $65.5 Billion-$67.0 Billion vs IBES Estimate $67.60 Billion
BRIEF-Merck Expects 2026 Sales $65.5 Billion-$67.0 Billion vs IBES Estimate $67.60 Billion Feb 3 (Reuters) - Merck & Co Inc MRK.N : MERCK OUTLOOK 2026 ADJUSTED EPS $5.00 - $5.15 VERSUS IBES ESTIMATE $5.36 MERCK Q4 ADJUSTED EPS $2.04 VERSUS IBES ESTIMATE $2.01 MERCK OUTLOOK 2026 SALES $65.5 BILLION-
02-03 19:30
Moderna Reports Five-Year Data Showing mRNA-4157 and Keytruda Cut Melanoma Recurrence Risk by 49%
Moderna Reports Five-Year Data Showing mRNA-4157 and Keytruda Cut Melanoma Recurrence Risk by 49% Moderna Inc. and Merck have announced median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, which evaluated adjuvant treatment with intismeran autogene in combination with
01-27 23:57
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results Jan 21 (Reuters) - Gilead Sciences Inc GILD.O : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE
01-22 06:18
VanEck Targets Nvidia, Microsoft Weight Caps With TruSector ETFs For Tech, Consumer Sectors
VanEck has new ETFs that aim to minimize tracking error by eliminating artificial limits on leading holdings.
2025-08-26 21:17
BRIEF-Merck And Eisai Provide Update On Phase 3 Leap-015 Trial
Jan 24 (Reuters) - Merck & Co Inc MRK.N: MERCK AND EISAI PROVIDE UPDATE ON PHASE 3 LEAP-015 TRIAL EVALUATING KEYTRUDA® (PEMBROLIZUMAB) PLUS LENVIMA® (LENVATINIB) IN COMBINATION WITH CHEMOTHERAPY IN PA...
2025-01-24 20:26
LIVE MARKETS-Nasdaq, S&P 500 get tech boost as tariff jitters ease
Nasdaq, S&P 500 advance; Dow closes slightly red Comm svcs leads S&P sector gainers; Real Estate weakest group Dollar down; gold, crude dip; bitcoin jumps >4% U.S. 10-Year Treasury yield edges up to ~...
2025-01-07 05:14
LIVE MARKETS-S&P 500 negative outlooks for Q4 above Q3 levels
Main U.S. indexes rally; Nasdaq out front, up ~1.4% Tech leads S&P sector gainers; Utilities weakest group Euro STOXX 600 index up ~1% Dollar slides; gold, crude dip; bitcoin up >3% U.S. 10-Year Treas...
2025-01-07 02:16
